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SUMMARY
Group B Streptococcus is the most common pathogen found in neonatal sepsis in North America.
OBJECTIVES: We describe 15 cases of neonatal infections by Group B Streptococcus (Streptococcus agalactiae) at a Neonatal
Intensive Care Unit of a public and teaching hospital.
METHODS: We conducted a study at Hospital de Clínicas de Porto Alegre, from January 1st, 1996 to June 30, 1999. Diagnosis
of neonatal infection was established according to the findings of Group B Streptococcus in blood culture associated with alterations
resembling sepsis on the basis of clinical picture and laboratory findings.
RESULTS: Fifteen cases of neonatal infections by Group B Streptococcus were detected. Eleven cases consisted of early-onset
sepsis, 2 cases of occult bacteremia and 2 cases of late-onset sepsis. Eight cases had septic shock (53%), 8 cases had pneumonia
(53%), and 4 cases had meningitis (27%). Fourteen cases were diagnosed from a positive blood culture, and 1 case from evidence of
these bacteria in pulmonary anatomopathological examination. Thirteen cases (87%) were diagnosed before 72 hours of life. We had
3 deaths (20%), and 3 cases of meningitis developing neurological deficits.
CONCLUSIONS: Streptococcus Group B is one of the most important pathogens in the etiology of early-onset neonatal sepsis
at our hospital, with high mortality and morbidity. However, we do not know the incidence of GBS neonatal infections at other
hospitals. More data are needed to establish a basis for trials of different strategies to reduce these infections.
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INTRODUCTION
Group B Streptococcus (GBS) is the main cause of perinatal bacterial
infections, including postpartum endometritis, chorioamnionitis, urinary
tract infection in pregnant women, and systemic/ focal infection in
newborns in North America1. Neonatal invasive disease is classified into
two groups based on its development after birth. Early-onset sepsis occurs
on average during the first 24 hours of life, varying from 0 to 6 days.
Late-onset sepsis appears between the third and the fourth week of life,
varying from 7 days to 3 months. Early-onset sepsis is characterized by
tachypnea, apnea, shock, and pneumonia and is frequently mortal. In
contrast, the latter is a less severe infectious disease accompanied by
meningitis1. In the United States, GBS sepsis rate was estimated at 12,000
cases/year, with approximately 1,600 deaths and 1,600 cases of
neurological deficits5. Since 1992, the Centers for Disease Control (CDC
– USA) has recommended application of intrapartum chemoprophylaxis
with high doses of penicillin G or intravenous ampicillin in the following
cases: (1) GBS in rectovaginal areas in women between 35–37 weeks of
pregnancy or (2) in the absence of these bacteria, the presence of high
risk factors for the development of neonatal GBS infection (previous
birth with GBS infection, bacteriuria with GBS, premature newborn,
intrapartum fever, premature rupture of membranes occurring more than
18 hours before delivery). GBS sepsis incidence later decreased to 7,600
cases/year in 1997, with 310 deaths and a cost estimated at US$ 700
million/year4,5,10.
We decided to present fifteen cases of GBS neonatal infections
diagnosed at Hospital de Clinicas de Porto Alegre (HCPA) since there
are few descriptions of this disease in Brazil.
MATERIAL AND METHODS
A retrospective study was conducted at the Neonatal Intensive Care
Unit of Hospital de Clinicas de Porto Alegre. All newborns who developed
GBS in blood cultures, cerebral spinal fluid (CSF), body fluids and
pulmonary anatomopathological piece were included in the study. Data
were obtained from the Service of Infection Control and the Service of
Medical Archives and Statistics. This project was approved by the
Commission of Research and Post Graduation and by the Committee of
Bioethics of Hospital de Clinicas de Porto Alegre. A peripheral blood
sample and central fluid from lumbar puncture were obtained from each
patient and submitted to a continuous monitoring system for bacterial
development in blood culture called BACTEC fluorescent series system
(Bactec® Becton Dickinson Microbiology System) in our Microbiology
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laboratory. The system uses 3 ml of infant blood added to a bottle
containing resins that release CO2 from infecting bacteria detected by an
infrared sensor which makes it fluorescent. In positive samples, the
microrganism was identified by colony morphology, hemolysis, and the
CAMP test for identification of Streptococcus agalactiae2,8. CSF and
body fluids were cultured on a Blood-Agar plate and positive samples
were processed as described for GBS identification8.
In our study, we considered: (1) sepsis as the pure development of
GBS in blood culture with clinical signs of infection which may vary
from fever, respiratory distress, convulsions, hypoactivity, or apnea,
associated with changes in laboratory parameters such as total neutrophil
count and immature to total neutrophil ratio (neutropenia less than 1,500/
mm3, immature to total neutrophils ratio higher than 0.2); (2) development
of GBS meningitis in CSF or more than 60% of neutrophils with more
than 30 leukocytes/mm3; (3) bronchopneumonia as respiratory distress
with pulmonary radiographic findings of diffused or confluent gross
opacifications; and blood culture with GBS.
RESULTS
Over a period of 3.6 years, we diagnosed 15 cases of neonatal GBS
infection; of these, 14 cases had positive blood culture and one had
pulmonary anatomopathological findings. In two cases, the patients
presented without symptoms: one newborn had occult bacteremia and
did not received antibiotics; the other had fever, bacteremia and
conjunctivitis, being treated with topical gentamicin.
Mean birth weight was 2,710 ± 745 grams (1,240-4,050 grams) and
mean gestational age was 36.9 ± 3.6 weeks, with the following
distribution: a case with 29 weeks, 5 cases with less than 35 weeks, and
9 cases with more than 38 weeks. Average time in early-onset sepsis
diagnosis was 1 day (0-15), distributed as it follows: 5 cases showed
signs of infection immediately after birth, 3 patients were diagnosed on
the first day, 3 on the second day, 2 on the third day, one on the 11th day,
and one on the 15th day of life. Therefore, we had 13 cases of early-onset
infections with an incidence of 1/1,000 live births (13,000 live births in
3.5 years) and 2 cases of late-onset infections.
Through medical chart review, we found 6 cases with maternal risk
factors (40%): 5 cases of premature labor, 3 cases of premature rupture
of membranes, and 2 cases of urinary tract infection. The clinical picture
of sepsis was accompanied by the following complications: 7 patients
needed mechanical ventilation, 3 needed concentrated, and 4 had
convulsions during the early stage of sepsis. Four cases of sepsis were
associated with meningitis, 8 had chest radiographs showing
bronchopneumonia, and 3 cases had characteristic findings of hyaline
membrane disease. We treated 10 patients with ampicillin plus gentamicin
for 10 days, 3 patients with crystalline penicillin G plus gentamicin, and
4 patients with the combination of vancomycin, cefotaxime plus amikacin
according of our second scheme of presumptive antibiotic therapy. The
following sequels were seen: one patient had periventricular
leukomalacia, 2 patients had persistent convulsions, and one patient had
associated neurosensory hearing loss. Three deaths occurred in premature
infants. One died with 12 hours of life of septic shock and pulmonary
hypertension, one died with 48 hours of life, and the third with three
days of life, both newborns with pulmonary hypertension and multiple
organ failure.
DISCUSSION
There are some studies describing the role of perinatal GBS infection
in Brazil and South America. The Brazilian studies are about the incidence
of colonization in pregnant women and their newborns. BENCHETRIT
at al.3 in 1982, for the first time in Brazil, detected GBS in 22 of 86
pregnant women (26%) and in 12 of their 78 newborn infants (15%).
SKLOVSKY at al.14 in 1983 in Porto Alegre described 4 cases of GBS
in 67 pregnant women (6%) and just one case of their newborn infants
(1.5%). SMÂNIA JUNIOR et al.15 in 1986 detected in Florianópolis 34
cases in 135 pregnant women (25%) and 16 cases in their newborns
(12%). There were two other studies in South America reporting a low
incidence of GBS colonization at the end of pregnacy. In 1995, in
Londrina, MOCELIN et al.9 detected 15 cases in 100 pregnant women
(15%) and COLLINS et al.6 detected a prevalence of 6% of vaginal
colonization by GBS in Peruvian pregnant women. These data represent
a low incidence compared to data reported for American women whose
prevalence is around 35%1,4,5. There is no report of the role of GBS
neonatal infections in Brazil. One study similar to ours was reported by
SARRUBI et al.12 in Buenos Aires, covering the period from 1984 to
1997, in which the authors detected 76 cases of neonatal infections by
GBS in 83,859 newborns, corresponding to an attack rate of 0.9 cases/
1,000 live newborns. These data were similar to our NICU and with the
same attack-rate for GBS early-onset sepsis of 1.0/1,000 live newborns.
Table 1
Demographic characteristics of neonatal infection by Group B Streptococcus
Demographic characteristics Number of cases (%) n = 15
Weight at birth (grams) 2 710 ± 745
Mean ± S
Pediatric gestational age (weeks) 36.9 ±3.6
Mean ± S
Maternal age (years) 23.8 (19-34)
Mean
Sex Male 7 (47%)
Female 8 (53%)
Fifth minute Apgar score 8.7 ± 0.8
Mean ± S
Septic shock 8 (53%)
Bronchopneumonia 8 (53%)
Meningitis 4 (27%)
Early-onset sepsis 11 (73%)
Late-onset sepsis 2 (13%)
Occult bacteremia 2 (13%)
Onset of the infection (days) 1
Mean (0-15)
Deaths 3 (20%)
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In the United States, intrapartum chemoprophylaxis reduced early-
onset sepsis attack rate to levels between 0.72 and 5.5/1,000 live newborn
infants. In premature infants weighing less than 1,500 grams the attack
rate is higher (7.6 and 26.2/1,000). In newborns at term this rate is lower
(0.5 and 1.5/1,000 live births) although 80% of the cases of early-onset
sepsis occur in term newborn infants. Mortality in the United States
ranges from 2% to 8% in term newborn infants and from 25% to 30% in
premature newborns1,5,10. STOLL et al.16 reported that GBS is currently
the most important pathogen in early-onset sepsis at 12 centers of neonatal
intensive care with a 31% incidence. In contrast, two studies published
outside the United States and Canada showed a low incidence of perinatal
GBS infection. KALLIOLA et al.7 reported 398 cases of early-onset
GBS neonatal infection over a period of 10 years, with an incidence of
0.63/1,000 live births in Finland, with a case fatality rate of 9.2%. They
diagnosed sepsis in 77% of cases, meningitis in 17% of cases, and
pneumonia in 3% of cases. MOSES et al.11 described data of 41 cases of
GBS early-onset sepsis that occurred from 1985 to 1996 in Oxford with
a low incidence of 0.5 per 1,000 live births (95% CI 0.4-0.7), and with a
19.5% mortality rate. All deaths occurred in preterm babies. They had
22 cases of sepsis, 13 of pneumonia, and 6 of meningitis. These results
outside North America are similar to ours with an attack rate of 1.0/
1,000 live newborns. However, these results may be unreliable because
our hospital receives high risk pregnancies with an adverse pregnancy
outcome.
Intrapartum chemoprophylaxis is very efficient and resulted in a
reduction from 1,600 to 310 deaths per year in the United States from
1993 to 19955, although some difficulties occurred in practice. The
screening is not always accepted by the obstetrician or by the pregnant
women. Moreover, the use of antibiotics has untoward effects like allergic
reactions, increase in bacterial resistance, increase of infections by gram-
negative bacteria, and secondary colitis13. Besides, it is known that
intrapartum antibiotics administered to pregnant women do not change
the course of the infection in early-onset sepsis by GBS in term NB4. It
is important to emphasize that no obstetric risk factors were detected in
approximately 25% to 30% of infected babies and about 30% of early-
onset sepsis cases and 10% of deaths are not covered by intrapartum
chemoprophylaxis4,10. When these intrapartum risk factors are present
we should investigate the infection and treat the infant. Definitive
diagnosis is confirmed by culture examination with development of GBS
and its serotype can be identified at reference laboratories. Treatment of
newborns with a presumptive diagnosis is based on the combination of
penicillin G or ampicillin with gentamicin. After confirmation of GBS
in culture, penicillin G or ampicillin treatment alone is adopted with
discontinuation of gentamicin. Although the optimum dosage is
unknown, it is recommended to administer 400,000 UI/kg/day of
penicillin G or 300 mg/kg/day of ampicillin, I.V. for 10 days in sepsis
and for 14-21 days in meningitis1.
CONCLUSION
Group B Streptococcus is one of the most important patohogens in
the etiology of early-onset neonatal sepsis at our hospital, with high
mortality and morbidity. However we do not know the incidence of GBS
neonatal infections at other hospitals. More data are needed showing the
importance of GBS in the etiology of neonatal sepsis to establish different
strategies for its reduction.
RESUMO
Infecção neonatal por Streptococcus do grupo B no Rio Grande do
Sul, Brasil
FUNDAMENTOS: Streptococcus do grupo B é o principal agente
etiológico responsável pela sepse neonatal na América do Norte.
OBJETIVOS: Relatar 15 casos de infecção neonatal por
Streptococcus do grupo B (Streptococus agalactiae) ocorridos na
Unidade de Tratamento Intensivo Neonatal de um hospital público e
universitário.
MÉTODO: O estudo foi realizado no Hospital de Clínicas de Porto
Alegre no período de 1º de janeiro de 1996 a 30 de junho de 1999. O
diagnóstico de infecção neonatal foi feito a partir do isolamento e
identificação de Streptococcus do grupo B em hemocultura combinado
com alterações clínicas e laboratoriais sugestivas de sepse.
RESULTADOS: Foram detectados quinze casos de infecção
neonatal por Streptococcus do grupo B, sendo onze casos de sepse de
origem precoce, dois casos de bacteremia oculta e dois casos de sepse
de origem tardia. Oito casos tiveram choque séptico (53%), oito casos
com pneumonia (53%) e quatro casos com meningite (27%). Quatorze
casos foram diagnosticados a partir da hemocultura e um caso através
da presença desta bactéria no exame anátomo-patológico do pulmão.
Treze casos (87%) foram diagnosticados antes de três dias de vida.
Ocorreram três óbitos (20%) e três pacientes com meningite ficaram
com seqüelas neurológicas.
CONCLUSÃO: O Streptococcus do Grupo B é uma das bactérias
mais importantes na etiologia da sepse neonatal de início precoce em
nosso hospital com elevada mortalidade e também com elevada
morbidade. Entretanto, não se conhece sua incidência em outros hospitais.
São necesssários outros estudos para determinar seu papel na sepse
neonatal e assim estabelecer diferentes estratégias para sua redução.
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